Decoy Therapeutics Inc. (DCOY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

DCOY scores 31 out of 100 for a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 4/20 (ROIC -35%; FCF yield 0%), Whale/13F Flow scores 3/20 (institutional accumulation and options positioning), Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the upside case rests almost entirely on the balance sheet and macro pillars, which are the only ones above the lower range. The weakest pillars—cash generation and ownership/insider conviction—are the ones that typically underpin a durable equity thesis, so their low scores weigh heavily against the stock. The shares' recent price move and the RQD verdict point in different directions, and the rating's framing is that short-term price action should not be read as a substitute for the underlying fundamentals. This is an educational breakdown, not personalized advice.

Decoy Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..

Operating losses appear in every reported period, and FCF is negative in each. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. The balance sheet is the strongest pillar in the RQD rating, though the reported debt line is N/A in all periods.

• 🐂 Primary Bull Case: Balance-sheet and macro pillars (Altman Z 2.5, Debt/Equity 0.5, Beta 1.0) are the strongest parts of the RQD rating, and the stock rose 11.82% on the day. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $0.90 – $47.22 52-week range.
• 🐻 Primary Bear Case: ROIC of -35%, zero revenue across all reported periods, negative FCF, and a 3/20 whale-flow score point to weak fundamentals and little institutional conviction. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies are — Sector correlation beyond the Beta of 1.0 is — Investors should note the absence of mapped dependencies rather than assume any particular ripple pattern.

• Key Question #1: What drives the positive reported net income in FY 2025 and FY 2024 when operating income and FCF are both negative?
• Key Question #2: What is the company's debt position, given the reported debt line is N/A and Debt/Equity is cited at 0.5?
• Key Question #3: What is the nature of the referenced merger-arbitrage activity, and how does it relate to the stock's trading range?